Gyre Therapeutics' Q2 revenue misses estimates
Overview
Gyre Q2 revenue of $26.8 mln missed analyst expectations, per LSEG data
Net income for Q2 was $1.6 mln, compared to $4.5 mln last year
Company reaffirmed full-year revenue guidance of $118-128 mln
Ping Zhang appointed interim CEO as Dr. Han Ying transitions to scientific role
Outlook
Gyre reaffirms 2025 revenue guidance of $118-128 mln
Result Drivers
NEW PRODUCT LAUNCHES - Revenue increase driven by launch of Etorel and Contiva, contributing $1.6 mln and $1.5 mln respectively
ETUARY DECLINE - Sales of ETUARY decreased due to weaker economic conditions and increased competition in the IPF market
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $26.77 mln | $30.80 mln (1 Analyst) |
Q2 Net Income |
| $1.58 mln |
|
Q2 Operating Profit |
| $2.17 mln |
|
Q2 Pretax Profit |
| $2.24 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Gyre Therapeutics Inc is $20.00, about 64.1% above its August 8 closing price of $7.19
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 21 three months ago
Press Release: ID:nGNXX3wJK
